Management Services Organizations (MSOs): How the Model Works in Healthcare Deals
An MSO is a company that, in the common structure, owns or leases the non-clinical assets of a medical or dental practice and runs everything except the practice of medicine under a long-term management services agreement (MSA). Licensed clinicians keep the professional entity (PC). Investors buy the MSO. The management fee, paid for real services at fair market value (FMV), becomes MSO EBITDA that can be valued, financed and sold. For a seller, that means three things. You trade part of your future income for cash, rollover equity and an earnout. The fee schedule sets how much you trade. And the cash you get at close is well below the headline price.
Key takeaways - The investor buys the MSA, not the practice. The fee schedule and its FMV support are the asset. - In our illustrative example, at a 25% markup and 10.0x, five points of fee markup move enterprise value by $3.3M. Two turns of multiple move it by the same amount. - Cash in hand at close is a fraction of the headline. With the illustrative terms used here it is 60% of enterprise value. - The fee prices bona fide services. A fee worked backward from the EBITDA a buyer wants is the first thing regulators and appraisers test.
Data as of November 20, 2026. Market figures come from PESP, Becker's ASC Review, Bain, FOCUS Investment Banking, SRS Acquiom, Damodaran (NYU Stern) and CMS, each linked where cited. All worked examples are illustrative. The inputs are our assumptions, not market benchmarks, and the arithmetic is ours.
The PC and MSO split: who owns what
| Function | Professional entity (PC, PA or PLLC) | MSO |
|---|---|---|
| Owners | Licensed physicians or dentists | Investors, founders, physicians who rolled equity |
| Diagnosis, treatment, clinical protocols | Controls | No role |
| Payer enrollment and contracts | Held in the PC's name | Runs billing and collections as agent |
| Physician employment | Employs clinicians | Employs non-clinical staff |
| Real estate, equipment, IT, EHR | Uses under lease or license | Owns or leases |
| Revenue | Collects professional fees | Earns the management fee |
| What a buyer values | Not sold | EBITDA after MSO costs |
| Governance | Board of licensed owners | MSA terms, budget process, transfer restriction agreement where state law permits one |
The model exists because states that apply the corporate practice of medicine (CPOM) doctrine limit whether lay-owned companies can employ physicians or direct clinical judgment. States vary widely in how strict the doctrine is, which professions it covers and how it is enforced, and several have tightened their rules since 2024. The analysis runs state by state with healthcare counsel. Dental runs a parallel version through dental service organizations (DSOs). Where state limits are lighter, a buyer can sometimes acquire the practice outright. Many still use the MSO so a multi-state platform runs one structure everywhere. The healthcare compliance due diligence guide and the Stark, anti-kickback and corporate practice of medicine guide cover the regulatory background.
An MSO structure fits when most of these are true:
- [ ] The practice operates in a state that limits lay ownership of medical or dental practices.
- [ ] The capital source, whether a PE sponsor, family office, strategic or health system, wants to own operations and earn a fee, not employ physicians directly.
- [ ] The plan is to add practices under one platform. A single-practice deal rarely justifies the legal and setup cost.
- [ ] Physicians will accept fixed or productivity-based pay in place of the full residual profit.
- [ ] Senior physicians will stay on as PC owners of record and clinical leaders.
- [ ] The practice can show clean, separable non-clinical costs that an MSO can absorb and run better.
MSO deal versus the other ways to take capital
| Route | What owners get | What owners give up | Fits when |
|---|---|---|---|
| Sell into a PE-backed MSO platform | Cash at close, rollover equity, earnout | Part of future practice profit for the life of the MSA. Exit timing set by the sponsor | Owners want liquidity now and a second payout at the platform sale |
| Form a physician-led MSO and sell a minority stake | Growth capital, control of the MSO board | Less cash up front. Owners carry operating risk | The group has management depth and wants to be the platform, not an add-on |
| Sell to a health system | Cash and employment terms | Independence. There is usually no equity upside | Referral fit with the system matters more than a second payout |
| Stay independent and borrow | Full ownership and profit | Personal guarantees and debt service | Capital needs are modest. SBA loan programs set loan limits that can change, so confirm the current rule with the lender |
7 documents that hold an MSO deal together
- Management services agreement (MSA). Defines the services, the fee, the budget process and termination rights. Buyers want long initial terms with automatic renewal and narrow PC termination rights. This is the asset the investor is really buying.
- Stock transfer restriction agreement. Also called a succession or continuity agreement. It governs who can own the PC's shares and when they must change hands. Regulators now scrutinize it closely, and some states restrict what it can contain.
- Asset purchase agreement. The MSO buys equipment, leases, IT, trade names and non-clinical goodwill. Sellers receive cash and often MSO equity. The purchase price allocation in this document drives the sellers' tax bill.
- Physician employment agreements. Signed with the PC. They set post-close pay, productivity metrics, term, and non-compete and non-solicit covenants.
- MSO holdco LLC agreement. Governs rollover equity, drag-along and tag-along rights, vesting and the waterfall at exit. Review it line by line with the physician rollover equity checklist.
- Leases and IP license. Covers the space, equipment and brand the PC uses.
- Fee schedule exhibit and FMV opinion. Sets out the fee math and an independent valuation showing that the fee and physician pay each sit within fair market value.
The management fee: four structures and how each is tested
The fee must reflect bona fide services the MSO delivers, priced at fair market value and structured to comply with the law of every state the platform operates in. It cannot simply be set to extract whatever profit is left in the practice. MSO fees are negotiated deal by deal against an FMV opinion and are not published in any market survey. The fee terms in the examples below are therefore illustrative inputs, not benchmarks.
| Fee structure | How it works | Buyer view | Pressure point |
|---|---|---|---|
| Fixed fee | Flat annual amount, repriced at scheduled resets | Predictable EBITDA. Caps MSO upside between resets | The MSO absorbs cost inflation and scope creep between resets. Reset dates and scope-change triggers belong in the MSA from day one, and each reset needs a fresh FMV opinion |
| Cost-plus | MSO costs plus a markup | Easiest to defend | The markup needs market support |
| Percentage of collections | Fixed share of PC net collections | Aligns with growth | Rises with volume and draws the closest regulatory review. Some states restrict it as fee-splitting |
| Residual sweep | PC pays physicians and a reserve, and the MSO takes the rest | Highest MSO EBITDA on paper | Hardest to support as FMV and reads as MSO control of the PC. Sophisticated buyers require it restructured before close |
Which structure fits which situation:
| Situation | Structure that usually fits | Why |
|---|---|---|
| Strict CPOM or fee-splitting state | Fixed fee or cost-plus | No fee that moves with practice revenue |
| MSO delivers marketing, intake or patient acquisition | Fixed fee or cost-plus | Keeps the fee from growing with business the MSO generates |
| Multi-state platform | Mix by state under one master MSA | One template, state-specific fee exhibits |
| Early-stage MSO with an unstable cost base | Cost-plus | Fee tracks real cost while the platform scales |
| Mature platform with benchmarked services | Fixed fee with scheduled FMV resets | Predictable EBITDA for lenders and exit buyers |
Worked example: what the fee structure does to value
Illustrative, our arithmetic. A six-physician medical dermatology group collects $12.0M a year. Non-physician operating costs, which the MSO absorbs, are $6.6M. Before the deal, physicians split $5.4M ($900K each). Assumptions: the MSO's cost base stays at $6.6M under every term, there are no other PC-level costs, and the platform is valued at an assumed 10.0x MSO EBITDA. The table shows how value moves with the fee. Whether any term is supportable depends on the services behind it.
| Fee term | Annual fee | Fee as % of collections | Markup on MSO costs | MSO EBITDA | Left in the PC for physicians | Enterprise value at 10.0x |
|---|---|---|---|---|---|---|
| A. Cost-plus, 15% markup | $7.59M | 63.3% | 15.0% | $0.99M | $4.41M | $9.9M |
| B. Cost-plus, 25% markup | $8.25M | 68.8% | 25.0% | $1.65M | $3.75M | $16.5M |
| C. Fixed fee | $8.70M | 72.5% | 31.8% | $2.10M | $3.30M | $21.0M |
Each point of markup on $6.6M of costs is worth $66K of EBITDA and $660K of enterprise value at 10.0x.
Sensitivity: enterprise value by markup and multiple (our arithmetic, $6.6M cost base)
| Markup on MSO costs | MSO EBITDA | EV at 8.0x | EV at 10.0x | EV at 12.0x |
|---|---|---|---|---|
| 15% | $0.99M | $7.92M | $9.90M | $11.88M |
| 20% | $1.32M | $10.56M | $13.20M | $15.84M |
| 25% | $1.65M | $13.20M | $16.50M | $19.80M |
| 30% | $1.98M | $15.84M | $19.80M | $23.76M |
Moving from a 25% to a 30% markup at 10.0x adds $3.3M. Moving from 10.0x to 12.0x at a 25% markup adds the same $3.3M. Buyers diligence the FMV opinion as hard as the financials for this reason, and sellers should expect the markup to be negotiated as hard as the multiple.
What FMV support for a fee looks like
A defensible fee is built line by line from the services the MSO delivers. Here is how Term C's 31.8% markup would have to be assembled. The line amounts are illustrative. The evidence column shows what an appraiser needs to see.
| Term C fee component (illustrative) | Annual amount | Evidence the FMV appraiser needs |
|---|---|---|
| MSO operating costs passed through | $6.60M | Cost allocations that match the service schedule, function by function |
| Management services margin, 15% of costs | $0.99M | Margins third-party practice managers earn for comparable scope |
| Brand and IP license | $0.60M | Royalty comparables and evidence the brand drives patient volume or pricing |
| Equipment and IT capital charge | $0.51M | A market return on capital the MSO funds, benchmarked to what the PC would pay to lease or finance it |
| Total fixed fee | $8.70M | $6.60M + $0.99M + $0.60M + $0.51M |
If the brand license or the capital charge cannot be supported with market evidence, the fee falls back toward Term A and value falls with it. An FMV opinion that states a conclusion without showing the service scope, the benchmarks and the basis for each line will not survive a buyer's diligence or a regulator's review.
Best practices on the MSA and fee:
- [ ] Write the service schedule to match what the MSO actually delivers, function by function.
- [ ] Price the brand or IP license, equipment and space in exhibits separate from management services.
- [ ] Commission the FMV opinion before signing and refresh it at every fee reset or material service change.
- [ ] Set the fee methodology in advance for the full term. Avoid mid-year changes.
- [ ] Keep marketing and patient acquisition out of any percentage fee.
- [ ] Give the PC a real budget approval role and record it in board minutes.
- [ ] Track MSO cost allocations so a cost-plus fee can be audited.
- [ ] Keep separate PC and MSO bank accounts with documented fund flows.
Payer mix, ancillaries and physician equity: what to map before the letter of intent
Government payer revenue, in-office ancillary services and physician-held equity are where the fee, physician pay and rollover terms get the closest review. Physician practices commonly bill Medicare and Medicaid. Dental revenue skews to commercial insurance and cash pay, but DSOs that treat Medicaid patients face similar questions. Mapping these facts before diligence starts makes the review concrete and shortens it.
| Fact to map | Why a buyer asks | What to prepare |
|---|---|---|
| Payer mix by payer type and state | Government payer share shapes how the fee and equity terms are reviewed | Trailing twelve months of collections by payer and state |
| In-office ancillaries such as lab, imaging and therapy | Revenue from services physicians order draws closer review of pay and ownership | Ancillary revenue by service line and by ordering physician |
| Physician pay formulas | Formulas that credit physicians with ancillary revenue get tested before signing | Current compensation plan and each physician's calculation for the last full year |
| MSO affiliates that physicians refer to | Rollover physicians referring to entities they hold equity in raises fraud and abuse questions | List of affiliates, ownership and referral volumes |
| Rollover equity terms | Buyers aim to offer physicians the same terms as other investors | Draft holdco terms showing unit class and price per unit |
| Billing and reassignment setup | Payers pay the PC, and the MSO bills as its agent | Enrollment records, reassignment and billing agency documents |
| Fee type | A fee that moves with volume gets more scrutiny than a fixed or cost-based fee | Fee schedule exhibit and the FMV opinion behind it |
Worked example: how the price is paid
Illustrative, our arithmetic. This uses fee term B from the example above: MSO EBITDA of $1.65M at 10.0x for a $16.5M enterprise value. Physicians keep $3.75M a year in the PC ($625K each, with no other PC-level costs assumed). The 70/20/10 split of consideration and the 10% escrow are assumed deal terms chosen to show the mechanics. They are not a market benchmark for MSO deals. The escrow is sized against enterprise value, treated here as the transaction value.
| Component | Share of EV | Amount | Per physician |
|---|---|---|---|
| Cash at close, before escrow | 70% | $11.55M | $1.925M |
| Indemnity escrow withheld from cash | 10% | ($1.65M) | ($0.275M) |
| Cash in hand at close | 60% | $9.90M | $1.65M |
| Rollover equity in the MSO | 20% | $3.30M | $0.55M |
| Earnout | 10% | $1.65M | $0.275M |
The trade. The group gives up $1.65M a year in pre-tax income ($5.4M less $3.75M), or $275K per physician. That reduction lasts as long as the MSA does. Under cost-plus it also grows when MSO costs grow, because the markup applies to a larger base. The table below shows how many years of the reduction each layer of consideration covers.
| Consideration received (cumulative) | Amount | Years of the $1.65M reduction covered |
|---|---|---|
| Cash in hand at close | $9.90M | 6.0 |
| Plus escrow released in full | $11.55M | 7.0 |
| Plus earnout paid at 43 cents on the dollar ($0.71M) | $12.26M | 7.4 |
| Plus rollover at an assumed 2.0x platform exit ($6.6M) | $18.86M | 11.4 |
Assumptions: flat collections, pre-tax, undiscounted, full escrow release with no claims, and an earnout that pays something. The 43 cents is SRS Acquiom's lower middle-market median among earnouts that paid anything (see below). Each layer after the first is less certain than the one before it. Physicians early in their careers should weigh the payback period against their remaining working years. Under cost-plus or a fixed fee, physicians keep most collections growth between resets. Under a percentage fee, they share it with the MSO.
Margin context. FOCUS Investment Banking's 2026 dermatology benchmarks report average operating margins of about 25% for medical dermatology, about 27% for cosmetic dermatology and 30% or more for medspa and aesthetics. Those are practice-level margins, not MSO EBITDA after a management fee. They frame the margin room a buyer looks for. They do not set the fee.
The earnout haircut. SRS Acquiom's 2026 Earnout and Milestone Trends study covers private-target deals. The right-hand column is the comparison figure SRS Acquiom reports for its 2014 to 2022 period.
| SRS Acquiom population | Earnout frequency, 2025 deals | SRS comparison figure, 2014 to 2022 period |
|---|---|---|
| Healthcare services targets | 37% | 26% |
| All deals, excluding life sciences | 24% | Not reported |
| U.S. private equity buyers | 24% | 13% |
| U.S. public buyers | 18% | 15% |
| Deals valued at $50M or less | 30% | 23% |
| Deals valued above $750M | 6% | 5% |
The same study reports that lower middle-market earnouts with any achievement paid a median of 43 cents on the dollar. Deals with upfront payments above $50M and any earnout success paid a median of 67 cents. Both medians exclude earnouts that paid nothing. Our $16.5M example sits in the lower middle market. If its $1.65M earnout pays anything, a median result would be about $0.71M ($1.65M × 0.43, our arithmetic). Zero is a live outcome. Model your own terms with the earnout value calculator.
The escrow assumption. SRS Acquiom's 2026 Deal Terms for M&A Escrows covers 2025 private-target deals across all industries, not healthcare alone.
| SRS Acquiom, 2025 deals, % of transaction value | Average | Median |
|---|---|---|
| General indemnity escrow, no RWI | 11.3% | 10.0% |
| General indemnity escrow, with RWI | 2.2% | 0.5% |
| Total escrow, no RWI | 14.7% | 11.1% |
| Total escrow, with RWI | 5.1% | 2.8% |
The illustrative 10% escrow matches the no-RWI median. At the with-RWI median of 0.5%, the escrow on $16.5M would be about $83K instead of $1.65M (our arithmetic). That gap is the case for pricing a reps and warranties policy. In the same 2025 data, 93% of deals had a purchase price adjustment mechanism, and 89% of those saw an actual adjustment. 28% of all deals had indemnification claims excluding purchase price adjustments, and 33% of deals with RWI did. Sellers' general reps survived closing in 43% of RWI deals and 89% of deals without RWI.
What sellers should negotiate:
- [ ] Rollover equity in the same class and at the same price per unit as the sponsor, with pro rata distributions.
- [ ] Tag-along rights and a clear drag-along price floor.
- [ ] Earnout metrics the physicians control, measured on a defined accounting basis, with acceleration on a platform sale.
- [ ] Escrow sized to the RWI policy where one is bought, with a fixed release date.
- [ ] A working capital target set from trailing months, not a single month.
- [ ] Compensation reset terms that hold for the full employment term.
- [ ] Fee reset mechanics in the MSA that the physicians can model, since every reset moves their income.
What the sellers keep after tax
The headline price is not taxed as one number. In an asset purchase, buyer and seller allocate the price across asset classes, and each class carries its own tax character. Five decisions drive the after-tax result. Model them with your tax advisor before the letter of intent, because the allocation is negotiated there.
| Decision | Why it moves the tax bill | Seller's position |
|---|---|---|
| Allocation to non-competes | Non-compete payments are ordinary income | Keep the allocation low and tied to a real covenant |
| Goodwill ownership | Goodwill can be capital gain, but whether the physician or the PC owns it depends on existing agreements | Settle ownership early. Existing non-competes with the PC point toward PC ownership |
| Entity type of the PC | A C corporation selling its own assets can face tax at the corporate level and again on distribution | Test a direct sale of personal goodwill where the physician owns it |
| Rollover structure | A contribution can defer tax. A taxable sale followed by reinvestment does not | Fix the structure in the letter of intent |
| Earnout terms | Payments tied to continued employment risk compensation treatment | Tie the earnout to business metrics, not to staying employed |
Applied to the example (our arithmetic): if $600K of the $11.55M cash ($100K per physician) is allocated to non-competes, that $600K is ordinary income. If the $3.3M rollover is structured as a taxable sale and reinvestment, the sellers owe tax on $3.3M of value they cannot sell until the platform exits.
High-risk area: MSO control and corporate practice of medicine
Ownership and control rules for medical practices, and what an MSO agreement can say, vary by state and change often. Bring these questions to a healthcare attorney before the letter of intent.
Questions to ask your attorney
1. In each state where our practices operate, which MSA and transfer restriction terms could be read as the MSO controlling the PC?
- Why ask: The MSA, budget rights and the stock transfer restriction agreement give the MSO its influence, and they are what the investor is paying for.
- What can go wrong: Terms that work in one state can be challenged in another, which forces a rewrite of the documents the valuation rests on.
2. Can the stock transfer restriction agreement be enforced as drafted in each state, and what happens if a PC owner dies, loses a license or leaves?
- Why ask: A succession gap at the PC level is a red flag in diligence and can stall a sale.
- What can go wrong: If the agreement cannot be relied on, the platform has no clean path to replace a PC owner of record.
- How one state has handled it: Oregon recently passed a law that limits when these agreements can be enforced (Holland & Knight, May 2026). Ask your attorney how each of your states treats them.
3. Is our planned fee structure, whether cost-plus, fixed or percentage of collections, likely to hold up in each state?
- Why ask: The fee is the MSO's EBITDA. In our example each point of markup moves enterprise value by $660K.
- What can go wrong: A fee restructured after close reduces MSO EBITDA and the value of the rollover equity and earnout tied to it.
4. Given our payer mix, in-office ancillaries and physician rollover equity, how should the fee, physician pay and equity terms be structured, and does the FMV opinion's scope cover each arrangement?
- Why ask: Government payer revenue and physician referrals to affiliated services bring federal referral and self-referral rules into the deal.
- What can go wrong: An FMV opinion that skips an arrangement leaves pay or equity terms unsupported in a buyer's or regulator's review.
5. If a state changes its rules after close, would our existing arrangements have to be restructured, and who bears that cost under the deal documents?
- Why ask: Sellers holding rollover equity and earnouts carry part of the risk of a forced restructuring.
- What can go wrong: A change in law can require new documents, a lower fee or a different structure in part of the footprint.
- How one state has handled it: Oregon's new law applies to new PC and MSO structures first and gives some existing arrangements more time to comply (Holland & Knight, May 2026). Ask your attorney which deadlines apply to your entities and whether a sale changes them.
6. Which federal and state transaction notice or review processes apply to this deal and to the planned add-ons, and how much lead time should the calendar carry?
- Why ask: A growing number of states have health care transaction notice or review laws, and the rules keep changing.
- What can go wrong: A review identified late can push closing, delay add-ons or reopen terms.
7. What protections can physicians holding rollover equity and an earnout negotiate if the platform underperforms, the MSA terminates or the platform fails?
- Why ask: In our example, 30% of enterprise value is paid in rollover equity and earnout, not cash.
- What can go wrong: If the platform fails, rollover equity and unpaid earnouts can be worth little or nothing.
8. If we raise MSO equity from physicians, family offices or other investors, how should the offering be handled, and does anyone we pay to raise it need to be registered?
- Why ask: Raising equity in the MSO is a securities offering, a separate area from healthcare law. Anyone paid to raise it can be checked on FINRA BrokerCheck.
- What can go wrong: An informal raise creates problems with investors and with later buyers in diligence.
Other topics to raise with your attorney
- Federal antitrust premerger notice for larger platform deals (FTC Premerger Notification Program) and local market overlap as the platform adds practices.
- Review of the fee, physician pay and rollover equity under federal referral and self-referral rules (HHS OIG fraud and abuse laws).
- Medicare enrollment, reassignment and billing agency arrangements between the PC and the MSO (CMS).
- Enforceability of physician non-compete and non-solicit covenants in each state.
- Ownership of patient records and EHR data, and privacy obligations between the PC and the MSO.
Where PE healthcare capital went in 2025, and who buys MSOs
The spending base behind MSO roll-ups keeps growing. Per the CMS National Health Expenditure fact sheet, physician and clinical services spending grew 8.1% to $1,109.7 billion in 2024. CMS projects it to grow 5.5% a year on average from 2025 to 2034.
| Subsector | PE-backed deals, 2025 (PESP) | Typical structure |
|---|---|---|
| Health IT | 151 | Direct company ownership, no MSO needed |
| Dental care | 149 | DSO and MSO platforms |
| Outpatient care | 148 | MSO platforms in physician specialties |
| Medtech | 117 | Direct company ownership |
| Behavioral health | 56 | Mixed. MSO where licensed clinicians deliver care |
The Private Equity Stakeholder Project's 2025 review, built on PitchBook and LevinPro HC data, tracked 1,029 PE-backed healthcare deals in 2025: 151 buyouts, 664 add-ons and 214 growth investments, involving 420 platform companies and 708 investment firms. PESP says its count is likely an underestimate. Dental is the purest MSO market. 95% of its 149 deals in 2025 were add-ons by PE-owned platforms, and 10 of the 18 platforms with the most deals were dental companies.
Within outpatient care, Becker's ASC Review, reporting PESP's 2025 data, counted 148 deals, led by dermatology at 24, eye care at 22 and oncology at 9. These are the specialties where MSO roll-ups are most mature. See Private Equity Physician Roll-Ups for how platforms build and exit.
Physician groups are losing share of deal flow. Bain & Company's Global Healthcare Private Equity Report 2026 reports physician groups falling from 28% of global provider transactions in 2021 to 23% in 2025. The exit buyer is shifting too. Bain cites McKesson's acquisition of ophthalmology and retina services provider Prism Vision Group from Quad-C Management, a strategic buying an MSO platform from a sponsor. To see which healthcare platforms have raised private capital, search Form D notices on SEC EDGAR full-text search.
Pricing reference points. The two public-market figures below measure different populations:
| Source and as-of date | Population | EV/EBITDA |
|---|---|---|
| FOCUS Investment Banking, Healthcare EBITDA Multiples: 2026 Dashboard | Median, publicly traded healthcare services companies, 2026 | About 11.5x, down from 14.5x the prior year |
| Aswath Damodaran, NYU Stern, EV/EBITDA by sector, January 2026 data | US Healthcare Support Services sector, 104 firms | 11.17x |
Both are public-company figures. They frame where an MSO platform's exit buyers trade. They do not price a private practice or platform directly, which is why the 10.0x on this page is an assumption.
See the healthcare multiples by segment and size chart. Segment and size detail is in Healthcare Valuation Multiples by Sector and Specialty.
What investors diligence in an MSO platform
Founders building an MSO, and physicians forming one before a sale, raise from sponsors, strategics and family offices. Each capital source reads the same file through a different lens.
| Capital source | What it optimizes for | What it presses on in diligence |
|---|---|---|
| PE sponsor | Add-on pace and an exit within the fund's hold period | Fee defensibility, add-on pipeline, lender-ready EBITDA |
| Family office | Long hold, steady cash yield, fewer forced exits | Fee stability, physician retention, downside protection |
| Strategic or health system | Fit with its network, referrals and payer contracts | Clinical integration, compliance history, market overlap |
| Physician-led MSO | Control and shared upside | Governance, equal-terms equity, capital for growth |
Structure and compliance - [ ] How is the management fee calculated, what services does it pay for, and who signed the FMV opinion? - [ ] Does the FMV opinion price each service line against market evidence? - [ ] What does the fee equal as a share of collections and as a markup on MSO costs? - [ ] Does any MSO affiliate furnish lab, imaging or therapy services that rollover physicians refer to? - [ ] Has the fee structure been tested against the law of every state the platform operates in? - [ ] What happens if a PC owner dies, loses a license or leaves, and does the transfer restriction agreement hold in each state?
Economics - [ ] What share of collections comes from the top three physicians, and what are their contract terms? - [ ] What did physician pay look like before and after the reset? - [ ] What is the payer mix by state, and what share is cash-pay? - [ ] How many add-ons closed last year, and at what average multiple? - [ ] How much EBITDA moves for each point of fee markup?
Timing - [ ] Which federal and state transaction reviews apply to the next three acquisitions, and how much lead time do they add? - [ ] Do any states in the footprint have new rules that require existing practices to restructure?
Red flags to fix before going to market:
| Finding | Why investors discount it | Fix before the first meeting |
|---|---|---|
| Residual sweep fee | FMV and control risk in one document | Convert to cost-plus or fixed fee with a current FMV opinion |
| FMV opinion missing, stale or conclusion-only | The fee, and so the EBITDA, is unsupported | Commission a line-by-line opinion tied to the service schedule |
| One PC owner of record near retirement | Succession gap at the PC level | Name successor owners and confirm the transfer restriction agreement holds |
| A few physicians drive most collections on short contracts | Key-person risk on the revenue base | Sign employment terms before the letter of intent |
| Marketing services inside a percentage fee | Fee grows with business the MSO generates | Move marketing to a fixed or cost-based exhibit |
| Commingled PC and MSO accounts | Undercuts the separation the structure depends on | Separate accounts and document fund flows |
Family office structures and check sizes are covered in How Family Offices Invest in Healthcare. The healthcare data room checklist turns this list into a data room.
Questions owners ask about MSOs
Do physicians still own the practice after an MSO deal?
Yes, in the standard structure. Licensed physicians keep the professional entity, its payer contracts and authority over diagnosis and treatment. The MSO owns or leases the non-clinical assets and earns a management fee for the services it delivers. Its influence comes from the management services agreement and, in many deals, a stock transfer restriction agreement covering the PC's shares. States differ on what those documents can say, so terms that work in one state can fail in the next.
How is the MSO management fee set and tested?
The fee pays for bona fide services the MSO delivers, priced at fair market value and structured to comply with the law of each state where the practice operates. It cannot simply be set to sweep whatever profit is left after physician pay. Common forms are fixed fees, cost-plus fees and percentage-of-collections fees. Buyers support the fee with an independent fair market value opinion that prices each service line against market evidence. Percentage fees rise with volume and draw the closest review.
Which regulatory reviews can apply to an MSO transaction?
It depends on where the practices sit, what the deal does and how large it is. Larger platform deals can trigger federal antitrust premerger notice. A growing number of states have health care transaction notice or review laws, and some name MSOs and private equity investors directly. These reviews can add months of lead time, so the filing analysis belongs in the deal calendar before the letter of intent is signed.
How much of the price is paid in cash at close in an MSO deal?
Less than the headline. SRS Acquiom's 2026 study found earnouts in 37% of 2025 healthcare services target deals. In SRS Acquiom's 2025 escrow data across all industries, the median general indemnification escrow on deals without reps and warranties insurance was 10.0% of transaction value. Rollover equity in the MSO takes a further share. In this page's illustrative example, a $16.5 million enterprise value produces $9.9 million of cash in hand at close.
Is the sale price taxed at capital gains rates?
Usually only part of it. In an asset sale the price is allocated across asset classes, and each class carries its own tax character. Non-compete payments and post-close salary are ordinary income. Goodwill can produce capital gain, but whether the physician or the PC owns it depends on the agreements already in place. Rollover deferral depends on how the exchange is structured, and earnouts tied to continued employment risk compensation treatment. The allocation is negotiated in the letter of intent, so model it before signing.
Sources
- CMS, National Health Expenditure fact sheet
- Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review
- Becker's ASC Review, PESP 2025 outpatient deal data
- Bain & Company, Global Healthcare Private Equity Report 2026, New Models of Value Creation for Physician Groups
- FOCUS Investment Banking, Healthcare EBITDA Multiples: 2026 Dashboard
- FOCUS Investment Banking, Dermatology Practice Valuation: 2026 Benchmarks
- Aswath Damodaran, NYU Stern, EV/EBITDA by sector (US), January 2026 data
- SRS Acquiom, 2026 M&A Earnout and Milestone Trends (2025 data)
- SRS Acquiom, 2026 Deal Terms for M&A Escrows (2025 data)
- Holland & Knight, An Update on the Implementation and Implications of Oregon's New CPOM Laws, May 2026
- SBA, 7(a) loan program
- SEC EDGAR full-text search
- FINRA BrokerCheck
- FTC, Premerger Notification Program
- HHS OIG, Fraud and abuse laws